Reported total revenue of $80.1 million for Q1 2026, compared to $64.9 million in Q1 2025. Net loss narrowed to $25.2 million in Q1 2026 from $40.5 million in Q1 2025. Product sales, net, increased to $43.4 million from $34.9 million in the prior year period. Completed the acquisition of Corstasis Therapeutics on April 2, 2026, for $75 million in upfront cash. Entered into a definitive merger agreement on May 1, 2026, to be acquired by Essence Parent Inc. for $3.16 per share plus a contingent value right (CVR). The merger is expected to close in the third quarter of 2026, subject to stockholder approval.